Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAIC sequential sintilimab versus intravenous chemotherapy plus sintilimab for advanced oligometastatic gastric cancer
ChiCTR2300075651Phase 3Recruiting
- Sponsor
- General Hospital of Eastern Military Command
- Start
- Sep 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sintilimab, oxaliplatin, tegafur and epirubicin in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by General Hospital of Eastern Military Command. Primary endpoint: Conversion rate of acceptable surgery after conversion therapy. Started Sep 2023; status: recruiting.
02
Drugs
sintilimaboxaliplatintegafurepirubicin
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300075651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075651.